University of Cambridge > Talks.cam > Cambiowebinars Seminar Series Feb-Apr 2015 > Lgr5 liver stem cells and Hepatic organoids

Lgr5 liver stem cells and Hepatic organoids

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Dr. Monica Vega-Hernandez.

Despite the enormous replication potential of the liver, there are currently no culture systems available that sustain hepatocyte replication in vitro. Hepatocytes can be maintained in culture for a few days. However, they lose their hepatocyte phenotype and function almost immediately, thus precluding its application for cell therapy treatments. Liver stem cells have the potential to self-renew and differentiate into functional hepatic lineages. We have recently described that, upon liver damage, the intestinal stem cell marker Lgr5 becomes highly expressed in the stem/progenitor cells that contribute to liver regeneration via de-novo generation of hepatocytes and ductal cells. Mouse liver stem cells can be indefinitely expanded in vitro (for >1 year), into “liver organoids”, in our novel liver stem cell culture system, in the absence of a mesenchymal niche. The cultured cells express ductal markers and differentiate into functional hepatocytes in vitro and in vivo. We have now further developed our culture system to study human liver stem cells and human liver disease. We describe a culture system that allows the long-term expansion of adult human liver stem cells (>3 months) from donor biopsies while maintaining their differentiation potential towards functional hepatocytes in vitro. The expanded cells are highly stable at the chromosome and structural level, while single base changes occur at very low rates. The cells can readily be converted into functional hepatocytes in vitro and upon transplantation in vivo. Organoids from α1-antitrypsin deficiency and Alagille Syndrome patients mirror the in vivo pathology. Clonal long-term expansion of primary adult liver stem cells opens up experimental avenues for disease modeling, toxicology studies, regenerative medicine and gene therapy.

This talk is part of the Cambiowebinars Seminar Series Feb-Apr 2015 series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.

 

© 2006-2019 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity